Sotigalimab clinical trials
Also written APX005M.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses sotigalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 8
Apexigen America, Inc. (4) · M.D. Anderson Cancer Center (2) · Yale University (2) · Pediatric Brain Tumor Consortium (1) · Alexander Z. Wei, MD (1) · Parker Institute for Cancer Immunotherapy (1) · BioNTech US Inc. (1) · Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1)
Often tested with
Tested in the same studies.
Synthetic Tumor-Associated Peptide Vaccine Therapy (1) · Cabiralizumab (1) · Nivolumab (1) · Personalized Peptide Cancer Vaccine NEO-PV-01 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sotigalimab.
- May 2027Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerPhase 1 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses sotigalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02600949Written as SotigalimabHow we know
- Phase I Study of APX005M in Pediatric Central Nervous System TumorsCompletedPhase 1Pediatric Brain Tumor ConsortiumNCT03389802Written as APX005M treatment for recurrent or refractory primary malignant CNS tumor patientsHow we know
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)CompletedPhase 1Yale UniversityNCT04495257Written as APX005MHow we know
- APX005M and Doxorubicin in Advanced SarcomaCompletedPhase 2Alexander Z. Wei, MDNCT03719430Written as APX005MHow we know
- APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02706353Written as APX005MHow we know
- APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaCompletedPhase 1Yale UniversityNCT03502330Written as APX005MHow we know
- APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction CancersCompletedPhase 2Apexigen America, Inc.NCT03165994Written as APX005MHow we know
- A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic MelanomaTerminatedPhase 2Apexigen America, Inc.NCT04337931Written as sotigalimabHow we know
- CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabCompletedPhase 1/2Apexigen America, Inc.NCT03123783Written as APX005MHow we know
- Study of the CD40 Agonistic Monoclonal Antibody APX005MCompletedPhase 1Apexigen America, Inc.NCT02482168Written as APX005MHow we know
- APX005M in Patients With Recurrent Ovarian CancerWithdrawnPhase 2Nordic Society of Gynaecological Oncology - Clinical Trials UnitNCT05201001Written as APX005MHow we know
- Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedPhase 1/2Parker Institute for Cancer ImmunotherapyNCT03214250Written as APX005MHow we know
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedPhase 1BioNTech US Inc.NCT03597282Written as APX005MHow we know
Given beside what is tested · 1 — sotigalimab is usual care or a partner of the new treatment
Codes
What other systems call sotigalimab · ClinicalTrials.gg INT001962
- MeSH (NLM) C000723517sotigalimabOne source ClinicalTrials.gov
- UNII (FDA) JEA93WJ5DGSOTIGALIMABOne source FDA
- NCI Thesaurus C123734SotigalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723517 | sotigalimab | One source ClinicalTrials.gov |
| UNII (FDA) | JEA93WJ5DG | SOTIGALIMAB | One source FDA |
| NCI Thesaurus | C123734 | Sotigalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.